TMCnet News
Statera Biopharma Advances Next-Gen Proprietary Compositions Based on STAT-200 PlatformIn collaboration with MolSoft, ImQuest, a Statera company, is investigating new, optimized compositions incorporating desirable elements of STAT-200 FORT COLLINS, Colo., March 07, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced advancement of its next-gen research activities that builds upon the immune modulation activity of STAT-200 on Toll-Like Receptors (TLRs) to improve drug characteristics and clinical benefit beyond opioid receptors. The research is based on the discovery that STAT-200, which originally was designed to antagonize opioid receptors, modulates multiple signaling pathways through receptors known as TLRs. These receptors act as master controllers of inflammation. Statera’s discovery platform identifies novel compositions that build upon STAT-200 by modulating multiple cellular targets, versus one, to restore cellular homeostasis. These findings have led to the selection of promising new compositions with the potential to treat a range of inflammatory-related diseases. “The platform could not have existed before the discovery of the effect of STAT-200 on TLRs,” said Stephen Wilson, PhD, Chief Innovation Officer at Statera. “With this knowledge, we have an immense opportunity to improve drug characteristics and clinical benefit because we aren’t limited to optimizations based on opioid receptors alone.” The platform rapidly screened billions of potential compositions, resulting in hundreds of promising targets. The top ten compositions were highly compelling, and three of them are currently being synthesized for biologic validation. Statera partnered with MolSoft, a leader in computational chemistry and bioinformatics software, to conduct the computational discovery through its proprietary Rapid Isostere Discovery Engine (RIDE) technology. “A paradigm shift is daring, but these initial findings have proven that Statera’s approach can identify actionable compositions that would be missed using traditional constrants,” said Dr. Andrew Orry, MolSoft’s Senior Research Scientist. Last year, Statera acquired ImQuest Life Sciences, Inc., which evaluates biologics and pharmaceuticals in preclinical development. ImQuest plans to begin functional validation of key compositions and expects to accumulate datasets to select the best leads for animal safety/efficacy testing in multiple indications. About Statera Biopharma Forward Looking Statements Given these uncertainties, you should not place undue reliance on these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. Contacts: Statera Biopharma FINN Partners |